19805 N. CREEK PARKWAY, BOTHELL, WA
Market cap: $9.8M (2/10/2026)
Price: $0.95
Compensation Committee Approves Stock Options for Directors and Officers
Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
To Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Announces Closing of Up To $13 Million Registered Direct Offering
Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Q3
Q2
Q1
FY 2024
FY 2023 amended
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload